SLN logo
SLN NASDAQ GB

Silence Therapeutics Plc - American Depository Share

Healthcare · Biotechnology Website · IPO Jan 2010
$5.94
▲ +$0.47 (+8.59%)
Vol 286K
5
Quality Score
fail
Mkt Cap
$287.2M
ROE
-98.1%
Margin
-241.3%
D/E
0.00
Beta
3.09
52W
$0–$3

Price Chart

Earnings

Beat rate: 0.0%
Quarter EPS Est EPS Act Surprise
Dec 2024 $0.21
Dec 2023 $-0.37

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -98.1% -98.1% -98.1% -98.1% -98.1%
P/E (TTM)
Net Margin -12211.6% -241.3% -241.3% -241.3% -241.3% -241.3%
Gross Margin 62.0% 66.0% 66.0% 66.0% 66.0% 66.0%
D/E Ratio 0.00 0.00 0.00 0.00 0.00
Current Ratio 8.95 8.95 8.95 8.95 8.95

Key Ratios

ROA (TTM)
-59.3%
P/S (TTM)
6.44
P/B
3.5
EPS (TTM)
$-0.97
CF/Share
$-0.33
Rev Growth 3Y
+315.5%
52W High
$2.63
52W Low
$0.50
$0.50 52-Week Range $2.63

How does SLN compare to Biotechnology peers?

Peer group: Micro-cap Biotechnology (All) · 528 companies

SLN valuation vs Biotechnology peers

P/E ratio
0% below peers (18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
6.4
50% below peers (12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
3.5
43% above peers (2.5)
vs Peers
vs Industry
Pricier
Div yield
0% below peers (0.0%)
vs Peers
vs Industry
Low yield

SLN profitability vs Biotechnology peers

ROE
-98.1%
46% below peers (-67.3%)
vs Peers
vs Industry
Weak
Net margin
-241.3%
16% above peers (-286.8%)
vs Peers
vs Industry
Weak
Gross margin
66.1%
16% below peers (78.6%)
vs Peers
vs Industry
Weak
ROA
-59.3%
27% below peers (-46.7%)
vs Peers
vs Industry
Below avg

SLN financial health vs Biotechnology peers

D/E ratio
0.0
0% below peers (0.0)
vs Peers
vs Industry
Low debt
Current ratio
9.0
102% above peers (4.4)
vs Peers
vs Industry
Strong liquidity
Beta
3.1
219% above peers (1.0)
vs Peers
vs Industry
More volatile

SLN fundamentals radar

SLN Peer median Industry

SLN profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

SLN vs peers: key metrics

Latest News

No related news yet